Clinical Trials Manager ©

Contact webmaster   Updated 09/03/2009 17:42:24 Trial status: Active Trials found: 388 Clinical Trials Network : Therapeutic group Cardiovascular IM/Other Liver Disease Department Division Anesthesiology Other Dermatology Cosmetic Dermatology Dermatology Clinic General Practice Pediatrics Medicine Cardiology Digestive & Liver Diseases Endocrinology General Medicine Hematology and Oncology Infectious Diseases Medical Oncology Nephrology Preventive Medicine & Nutrition Pulmonary Cardiology Pulmonary, Allergy & Critical Care Medicine Rheumatology Neurological Surgery Epilepsy Movement Neuro Surgeon Neurooncology Spine Neurology Dementia and Aging Epilepsy G H Sergievsky Center General Neurology Movement Disorders Movement Disorders/neuromuscular Multiple Sclerosis and Demyelinating Diseases Neuromuscular Disease Neurooncology Stroke and Critical Care Obstetrics and Gynecology Family Planning & Preventive Services Gynecologic Oncology Maternal Fetal Medicine Menopause Obstetrics and Gynecology Reproduction and Endocrinology Ophthalmology Glaucoma Macula Surgical & Medical Retinal Disease Ophthalmology Other Orthopedic Surgery Lower Extremity and Reconstruction Otolaryngology/head and Neck Surgery Head & Neck Surgery Pathology Hemopathology Pediatrics Autoimmune & Molecular Diseases Cardiology Endocrinology Gastroenterology & Nutrition Hematology and Blood and Marrow Transplant Infectious Diseases Neonatology & Perinatal Medicine Oncology Pulmonary Rheumatology Psychiatry Behavioral Medicine Child Psychiatry Geriatrics Neuroscience Other Substance Abuse Radiation Oncology Radiation Oncology Radiology Interventional Radiology Neurosurgery School Of Dental and Oral Surgury Periodontics Surgery Allen General Surgery Cardiothoracic Surgery Center For Liver Disease & Transplantation Surgical Oncology Surgical Specialties Vascular Surgery Urology Oncology Trial details Clinical Trials Network Group : Cardiovascular ACCOMPLISH - Prospective, multinational, multicenter, double-blind, randomized, active-controlled, trial to compare effects of Lotrel to benazepril & hydrochlorothiazide combined on reduction of cardiovascular morbidity & morality patients w/ high risk hy   Principal Investigator: Mathew Maurer   Start date: 03/24/2004 End date: 12/24/2009 to request information from Principal Investigator.    Top of page ACCORD - N01 HC 95184/Action to Control Cardiovascular Risk in Diabetes   Principal Investigator: J. Thomas Bigger, Jr.   Website: www.accord-ne.org Start date: 09/30/1999 End date: 04/30/2010 to request information from Principal Investigator.    Top of page ACCORD-Eye - Action to Control Cardiovascular Risk in Diabetes -- Eye Substudy   Principal Investigator: J. Thomas Bigger, Jr.   Website: Start date: 11/01/2003 End date: 04/30/2010 to request information from Principal Investigator.    Top of page RO4607381 - Phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS). Reseach on pde-5 inhibitors' like influence on erectile function in men   Principal Investigator: J. Thomas Bigger, Jr.   Start date: 12/15/2008 End date: 06/30/2011 to request information from Principal Investigator.    Top of page Clinical Trials Network Group : IM/Other ITNTWK - Proleukin and Rapamune in Recent-onset Type 1 Diabetes Mellitus: Phase 1   Principal Investigator: Robin S. Goland (CTN)   Start date: 10/15/2008 End date: 09/14/2011 to request information from Principal Investigator.    Top of page Clinical Trials Network Group : Liver Disease ENTECAVIR-INCOMPLETE - FUNDED ACCOUNT: Protocol No. AI463-026-045 A Phase III Study of the Comparison of Entecavir to Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Current Lamivudine Therapy   Principal Investigator: Robert S. Brown   Start date: 04/16/2002 End date: 02/02/2010 to request information from Principal Investigator.    Top of page Department : Anesthesiology Division : Other Fixed dose of sucutaneous methylnaltrexone in adults with advanced illness and opioid induced constipation.   Principal Investigator: Michael Weinberger   Start date: 05/28/2008 End date: 11/30/2013 to request information from Principal Investigator.    Top of page Department : Dermatology Division : Cosmetic Dermatology Early Diagnosis of Melanoma - Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells.   Principal Investigator: Julide T Celebi   Start date: 04/10/2008 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Department : Dermatology Division : Dermatology Clinic **STUDY MGR**A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients with Stage I or IIA Mycosis Fungoides (MF)   Principal Investigator: Elizabeth Knobler   Start date: 06/12/2007 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Nitrogen Mustard 0.04% - Open Label Six Month Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.04% Ointment Formulation in Patients with Stage I or IIA Mycosis Fungoides (MF) Who Have Completed an Initial 12 Month Treatment with Nitrog   Principal Investigator: Elizabeth Knobler   Start date: 02/14/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Department : Dermatology Division : General Practice **STUDY MGR** An Un-blinded Exploratory Study to Evaluate a Cutaneous Incisional Wound Model of Mast Cell Infiltration in Healthy Volunteers and Idiopathic Pulmonary Fibrosis (IPF) Patients   Principal Investigator: Julian Mackay-Wiggan   Start date: 12/13/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page M03-658 - Multicenter, Open-Label, Continuation Study in Moderate to Severe Chronic plaque Psoriasis Subjects who Completed a Preceding Psoriasis Clinical Study with Adalimumab   Principal Investigator: Julian Mackay-Wiggan   Website: smills@parabio.com Start date: 09/14/2005 End date: 09/06/2009 to request information from Principal Investigator.    Top of page Observational Post-marketing Safety Surveillance Registry of Enbrel (etanercept) for Treatment of Psoriasis   Principal Investigator: Julian Mackay-Wiggan   Start date: 07/20/2006 End date: 02/28/2016 to request information from Principal Investigator.    Top of page Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail   Principal Investigator: Julian Mackay-Wiggan   Start date: 05/11/2007 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Department : Dermatology Division : Pediatrics APPLES - Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis   Principal Investigator: Kimberly D. Morel   Start date: 11/22/2005 End date: 09/30/2020 to request information from Principal Investigator.    Top of page Prospective, Multicenter, within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects with Junctional or Dystrophic Epidermolysis Bullosa   Principal Investigator: Kimberly D. Morel   Start date: 05/11/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Department : Medicine Division : Cardiology **STUDY MGR*A Rdmzd, OL Study to Compare the Safety and Efficacy of Conversion From A Calcineurin Inhibitor to Sirolimus Verus Continued Use of a Calcineurin Inhibitor in Cardiac Transplant Rcpnts w/Mild to Moderate Renal Insufficiency   Principal Investigator: Donna Mancini   Start date: 12/15/2006 End date: 06/30/2011 to request information from Principal Investigator.    Top of page 123I-mIBG - Open-Label, Multicenter, Phase 3 study Evaluating the Prognostic Usefulness of 123 I-mlBG Scintigraphy for identifying subjects with heart failure who will experience an adverse cardiac event   Principal Investigator: Sabahat Bokhari   Start date: 08/25/2005 End date: 12/31/2010 to request information from Principal Investigator.    Top of page ADAPT DES - ADAPT DES Study: Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents   Principal Investigator: Giora Weisz   Start date: 06/04/2008 End date: 01/31/2015 to request information from Principal Investigator.    Top of page CHAMPION - CHAMPION: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients.   Principal Investigator: Donna Mancini   Start date: 07/09/2008 End date: 05/01/2012 to request information from Principal Investigator.    Top of page CHAMPION - Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects who Require Percutaneous Coronary Intervention   Principal Investigator: George Dangas   Start date: 04/24/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page COSTAR II - Cobalt Chromium Stent with Antiproliferative for Restenosis II Trial   Principal Investigator: Michael Collins   Website: Start date: 06/08/2005 End date: 12/31/2009 to request information from Principal Investigator.    Top of page CREST - RO1 NS38384/Carotid Revascularization Endarterectomy vs. Stent Trial   Principal Investigator: William Gray   Start date: 10/10/2008 End date: 12/31/2011 to request information from Principal Investigator.    Top of page CUPID Trial - Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease   Principal Investigator: Donna Mancini   Start date: 05/04/2007 End date: 11/30/2012 to request information from Principal Investigator.    Top of page Complete SE Registry - **STUDY MANAGER** Complete SE Registry: Percutaneous interventional treatment of iliac artery lesions using the Medtronic Complete® Self-Expanding (SE) Iliac Stent.   Principal Investigator: William Gray   Start date: 04/15/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page DETERMINE - Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation   Principal Investigator: Fredrick A Ehlert   Start date: 09/12/2008 End date: 01/07/2013 to request information from Principal Investigator.    Top of page Double-blind, prospective, randomized, placebo-controlled study to determine the tolerability, efficacy, safety, and dose range of intramyocardial injections of G-CSF mobilized Auto-CD34+ cells for reduction of angina episodes in pts with refractory   Principal Investigator: Warren Sherman   Start date: 08/14/2006 End date: 02/28/2011 to request information from Principal Investigator.    Top of page EMPIRE - **STUDY MANAGER** Embolic Protection with Reverse Flow Study of the Gore Neuro Protection System in Carotid Stenting of Subjects at High Risk for Carotid Endarterectomy   Principal Investigator: William Gray   Start date: 10/08/2007 End date: 03/31/2010 to request information from Principal Investigator.    Top of page ENDEAVOR 4 - **STUDY MANAGER** Randomized, controlled trial of the medtronic endeavor drug(ABT-578) eluting coronary stent system vs. the Taxus Paclitaxel-eluting coronary stent system in de novo native coronary lesions   Principal Investigator: Jeffrey W. Moses   Start date: 05/12/2005 End date: 11/30/2010 to request information from Principal Investigator.    Top of page ENDEAVOR SVS - **STUDY MANAGER** Endeavor SVS Registry: A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novo Lesions in Small Diameter Native Coronary Arteries.   Principal Investigator: Jeffrey W. Moses   Start date: 06/10/2008 End date: 10/31/2013 to request information from Principal Investigator.    Top of page EVEREST II - **STUDY MANAGER** A study of the Evalve Cardiovascular Valve repair system (CVRS) endovascular valve edge-to-edge repair study   Principal Investigator: William Gray   Start date: 03/21/2005 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Lightlab M4 - **STUDY MANAGER** Evaluation of the M4 System for Imaging Stented Coronary Arteries-Device trial   Principal Investigator: Jeffrey W. Moses   Start date: 10/27/2008 End date: 04/30/2011 to request information from Principal Investigator.    Top of page MYOHEART - Myogenesis Heart Efficiency and Regeneration Trial   Principal Investigator: Warren Sherman   Start date: 07/11/2006 End date: 01/31/2012 to request information from Principal Investigator.    Top of page MediGuide Trial - **STUDY MANAGER** MediGuide Trial: Medical Positioning System (MPS) In Conjunction with Guided Measurement Catheter (GMC™) Feasibility Study in Clinical Routine.   Principal Investigator: Giora Weisz   Start date: 03/09/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized with Worsening Renal Function   Principal Investigator: Paolo C. Colombo   Start date: 12/19/2007 End date: 07/31/2011 to request information from Principal Investigator.    Top of page Optivol Study - Correlation Between T Wave Alternans and Intrathoracic Impedance Measurements Using Optivol T Wave Alternans/Optivol Study.   Principal Investigator: Jose Dizon   Start date: 04/28/2007 End date: 10/31/2010 to request information from Principal Investigator.    Top of page PARTNER - **STUDY MANAGER** The PARTNER Trial: Placement of Aortic Transcatheter Valves Trial   Principal Investigator: Martin Leon   Start date: 05/29/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page PROTECT-II - multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure signs and renal impairment who are hospi   Principal Investigator: Maryjane A. Farr   Start date: 02/14/2008 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Pacing Chronotropic Incompetence - Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate For Six Hours in Patients With Congestive Heart Failure, Heart Rate <70 Beats per Minute and Fluid Overload.   Principal Investigator: Paolo C. Colombo   Start date: 06/16/2008 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Perseus Trial - **STUDY MANAGER** Perseus Trial: A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS[r] ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment   Principal Investigator: Jeffrey W. Moses   Start date: 01/28/2008 End date: 08/31/2013 to request information from Principal Investigator.    Top of page Perseus Workhorse Trial - **STUDY MANAGER** Perseus WorkhorseTrial: A Prospective Evaluation in a Non-Randomized of the Safety and Efficacy of the Use of the TAXUS (R) ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment   Principal Investigator: Jeffrey W. Moses   Start date: 01/28/2008 End date: 08/31/2013 to request information from Principal Investigator.    Top of page Power Disc-15 - Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution Delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15   Principal Investigator: Evelyn M Horn   Start date: 06/19/2007 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Protect II (IMPELLA) - **STUDY MANAGER** PROTECT II: A Prospective, multi-center randomized controlled trial of the IMPELLA® RECOVER® LP 2.5 System versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non-Emergent High Risk PCI   Principal Investigator: Michael Collins   Start date: 04/10/2008 End date: 10/31/2009 to request information from Principal Investigator.    Top of page RED-HF Trial - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction   Principal Investigator: Donna Mancini   Website: Start date: 11/06/2006 End date: 05/31/2010 to request information from Principal Investigator.    Top of page REVERSE - Resynchronization reverses remodeling in systolic left ventricular dysfunction study, REVERSE   Principal Investigator: Evelyn M Horn   Start date: 02/03/2006 End date: 12/31/2011 to request information from Principal Investigator.    Top of page RIDE - The Impact of Cardiac Resynchronization Therapy Optimization on Indices of Mechanical Dyssynchrony during Exercise.   Principal Investigator: Fredrick A Ehlert   Start date: 04/22/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page RIGHT - Rhythm ID going head to head Trial   Principal Investigator: Jose Dizon   Start date: 03/30/2006 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Randomized Double blind placebo controlled parallel group trial to assess the efficacy and safety of Omacor for the prevention of recurrent symptomatic Atrial fibrillation   Principal Investigator: James A. Reiffel   Start date: 02/13/2007 End date: 08/31/2011 to request information from Principal Investigator.    Top of page Scoring Balloon Catheter - **STUDY MANAGER** AngioSculpt bifurcation trial: AngioSculpt scoring balloon catheter coronary bifurcation study protocol   Principal Investigator: Jeffrey W. Moses   Start date: 06/20/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page T-wave Alternans and Ischemia - T-wave Alternans During Percutaneous Coronary Interventions.   Principal Investigator: Jose Dizon   Start date: 04/28/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page THAOS - Global, Multi-Center, Longitudinal, Observational Survey of Patients with Documented Transthyretin (TTR) Mutations or Wild-Type TTR Amyloidosis.   Principal Investigator: Matthew Maurer   Start date: 12/04/2007 End date: 06/30/2018 to request information from Principal Investigator.    Top of page THAOS Sub-Study - Sub Study: TRANSTHYRETIN-ASSOCIATED AMYLOIDOSES OUTCOMES SURVEY (THAOS)-Optional Blood Sample Collection Sub-Study   Principal Investigator: Matthew Maurer   Start date: 05/16/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page TOPCAT - Treatment of Preserved Cardiac function heart failure with an Aldosterone antagonist   Principal Investigator: Matthew Maurer   Start date: 03/23/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Tailored Treatment of Permanent Atrial Fibrillation using the Ablation Frontiers Cardiac Ablation System   Principal Investigator: Hasan Garan   Start date: 04/23/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page USE-BNP - Utilizing, Studying, Evaluating BNP for Monitoring in Patients with Heart Failure (USE-BNP).   Principal Investigator: Susan Restaino   Start date: 06/24/2008 End date: 12/31/2010 to request information from Principal Investigator.    Top of page VIBRANT - GORE VIABAHN ENDOPROSTHESIS VS. BARE NITINOL STENT IN THE TREATMENT OF LONG LESION SUPERFICIAL FEMORAL ARTERY OCCLUSIVE DISEASE   Principal Investigator: William Gray   Start date: 05/31/2006 End date: 11/30/2010 to request information from Principal Investigator.    Top of page ZoMAXX - **STUDY MANAGER** The ZoMAXX II trial: Randomized, controlled trial to evaluate the safety and efficacy of the ZoMaxx des system as compared to the TAXUS Express 2 DES in de novo coronary artery lesions   Principal Investigator: Martin Leon   Start date: 01/14/2005 End date: 07/31/2012 to request information from Principal Investigator.    Top of page Department : Medicine Division : Digestive & Liver Diseases Cryospray Study - Prospective, multi-center, longitudinal cohort study of Cryospray Ablation of low grade or high grade dysplasia within Barrett's esophagus (LCD Dysplasia).   Principal Investigator: Charles J. Lightdale   Start date: 10/30/2008 End date: 04/30/2011 to request information from Principal Investigator.    Top of page Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001.   Principal Investigator: Peter Green   Start date: 01/29/2009 End date: 07/31/2010 to request information from Principal Investigator.    Top of page SpyGlass Retro - MultiSite, Retrospective Chart Review of Cholangioscopic Procedures using the SpyGlass(TM) Direct Visualization System   Principal Investigator: Peter Stevens   Start date: 04/22/2008 End date: 10/31/2013 to request information from Principal Investigator.    Top of page Study of the Effect of Varying Biopsy Forceps Size on Adequacy of Tissue Acquisition in Barrett's Esophagus   Principal Investigator: Charles J. Lightdale   Start date: 03/31/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Department : Medicine Division : Endocrinology 24-Week, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of PPM-204 in Subjects With Type 2 Diabetes   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 05/23/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page ACROSTUDY - ACROSTUDY Multicenter, Post-Marketing Surveillance study of Somavert Therapy in Patients with Acromegaly in the US and Europe   Principal Investigator: Pamela Freda   Start date: 05/02/2006 End date: 11/30/2011 to request information from Principal Investigator.    Top of page AIM-HIGH - ATHEROTHROMBOSIS INTERVENTION in METABOLIC SYNDROME with Low HDL/HIGH TRIGLYCERIDE and IMPACT ON GLOBAL HEALTH OUTCOMES   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 05/15/2006 End date: 11/30/2010 to request information from Principal Investigator.    Top of page AVD111179 - 52 week randomized, double-blind, multicenter, mechanistic study with a 24 week open-label follow-up to evaluate the effect of AVANDIA on bone in postmenopausal women with type 2 diabetes mellitus   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 12/15/2008 End date: 02/28/2012 to request information from Principal Investigator.    Top of page Amylin Protocol - Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects with Type 2 Diabetes Mellitus Tre   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 03/10/2008 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Assessment of Cardiovascular Risk Markers in GH Deficient Patients with Non-secreting Pituitary Adenomas. Abbreviated Title: Cardiovascular Risk Markers in GH Deficiency   Principal Investigator: Pamela Freda   Start date: 05/05/2008 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors in Adult Patients with Growth Hormone Deficiency. Abbreviated Title:   Principal Investigator: Pamela Freda   Start date: 04/28/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page ELIXIR Study - Rapid onset and short duration Insulin Secretagogue, Mitiglinide, in combination with Metformin versus Metformin alone in patients with Type 2 Diabetes Mellitus: A randomized, doubleblind, placebo controlled trial for 6 months.   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 02/05/2008 End date: 08/31/2010 to request information from Principal Investigator.    Top of page Effects of Leptin Administration on Body Weight and Neuroendocrine Function in Weight-Reduced Individuals After Roux-en-Y Gastric Bypass Surgery. (Leptin After Gastric Bypass)   Principal Investigator: Judith Korner   Start date: 01/04/2008 End date: 07/31/2010 to request information from Principal Investigator.    Top of page HypoCCS - The Global Hypopituitary Control and Complications Study   Principal Investigator: Pamela Freda   Start date: 08/24/2006 End date: 02/28/2012 to request information from Principal Investigator.    Top of page IMMPRESS - Phase 3, Multi-Center, Open-Label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Mild Obstructive Pulmonary Disease Over a 12-Month Treatment Period with a   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 12/15/2008 End date: 06/30/2012 to request information from Principal Investigator.    Top of page IOOV - The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 04/06/2006 End date: 10/31/2009 to request information from Principal Investigator.    Top of page IOP Forteo - Teriparatide For the Treatment of Idiopathic Osteoporosis in Premenopausal Women.   Principal Investigator: Elizabeth Shane   Start date: 06/24/2008 End date: 03/31/2012 to request information from Principal Investigator.    Top of page MK-0431A - Phase III Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0431 in Patients with Type 2 Diabetes Mellitus   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 04/30/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Multi Center, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density   Principal Investigator: Elizabeth Shane   Start date: 07/18/2006 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Multi-center, open label study to assess the ability of subjects with acromegaly, or their partners, to administer Somatuline Autogel   Principal Investigator: Pamela Freda   Start date: 04/17/2007 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs Octreotide LAR in patients with Active Acromegaly   Principal Investigator: Pamela Freda   Start date: 02/25/2008 End date: 08/31/2011 to request information from Principal Investigator.    Top of page ONJ Markers - Biomarkers for bisphosphonate-associated osteonecrosis of the jaw in patients with breast cancer: a cross-sectional case control study   Principal Investigator: John P. Bilezikian   Start date: 04/09/2007 End date: 10/31/2009 to request information from Principal Investigator.    Top of page ORIGIN - Outcome Reduction with Initial Glargine Intervention   Principal Investigator: Susana Ebner   Start date: 06/30/2004 End date: 10/08/2009 to request information from Principal Investigator.    Top of page ORIGIN Trial - MC, International, Randomized, 2x2 Factorial design study to evaluate the effects of Lantus (Insulin Glargine) Vs Standard Care and of Omega-3 Fatty Acids Vs Placebo, in Reducing Cardiovascular Morbidity and...., IGT Early Type 2 Diabetes M   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 05/20/2005 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In Treatment of Type 2 Diabetes Mellitus In Treatment-Naive Subjects   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 09/25/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Randomized, double-blind study to assess the safety and efficacy of different dose levels of pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing's disease.   Principal Investigator: Pamela Freda   Start date: 04/19/2007 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Substudy - A 52 week randomized, dobule-blind, multicenter, mechanistic study with a 24 week open-label follow-up to evaluate the effect of AVANDIA on bone in postmenopausal women with type 2 diabetes mellitus   Principal Investigator: John P. Bilezikian   Start date: 11/17/2008 End date: 05/30/2012 to request information from Principal Investigator.    Top of page The Effects of PTH on the Skeleton in Hypoparathyroidism   Principal Investigator: John P. Bilezikian   Start date: 04/27/2007 End date: 10/31/2009 to request information from Principal Investigator.    Top of page VIAJECT 06J - An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 11/26/2007 End date: 05/31/2010 to request information from Principal Investigator.    Top of page VIAJECT 08J - An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus   Principal Investigator: Daniel S. Donovan, Jr.   Start date: 11/26/2007 End date: 05/31/2010 to request information from Principal Investigator.    Top of page Zolendronic Acid - Zoledronic Acid vs Alendronate for prevention of Bone Loss after Organ Transplantation   Principal Investigator: Elizabeth Shane   Start date: 06/02/2005 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Medicine Division : General Medicine Diagnostic Labelling: Effect on White coat Hypertension   Principal Investigator: Tanya Goyal   Start date: 07/15/2007 End date: 05/31/2011 to request information from Principal Investigator.    Top of page PA-04-107 - Improving Med Adherence in Post-ACS Patients: Phase IB Dose-Finding RCT   Principal Investigator: Karina W. Davidson   Start date: 09/01/2006 End date: 07/31/2011 to request information from Principal Investigator.    Top of page RCT of Controlled Breathing Effects on Ambulatory BP   Principal Investigator: William Gerin   Start date: 09/01/2007 End date: 08/31/2012 to request information from Principal Investigator.    Top of page Rheos Pivotal Trial - Rheos Baroreflex Hypertension Therapy System CONSULTING AGREEMENT   Principal Investigator: Thomas Pickering   Start date: 04/12/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page SPIRATE - RESPERATE hypertension randomized controlled trial   Principal Investigator: Lynn Clemow   Start date: 07/01/2008 End date: 06/30/2013 to request information from Principal Investigator.    Top of page Department : Medicine Division : Hematology and Oncology **STUDY MANAGER** A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy.   Principal Investigator: Daniel P. Petrylak   Start date: 03/15/2006 End date: 09/30/2011 to request information from Principal Investigator.    Top of page **STUDY MANAGER** Baxter TRAC-R: A 12-month follow-up double-blind, prospective, randomized, placebo-controlled study to dtermine the tolerability, efficacy, safety, and dose range of intramyocardial injections of G-CSF mobilized Auto-CD34...   Principal Investigator: William Sherman   Start date: 09/10/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page ...Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximad Compared to a Defined Invetigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22-Positive, Follicular B-Cell Non Hodgkin's Lymphoma   Principal Investigator: Owen O'Connor   Start date: 05/27/2008 End date: 11/30/2013 to request information from Principal Investigator.    Top of page 263 Trial - ABT-263: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies   Principal Investigator: Owen O'Connor   Start date: 04/27/2007 End date: 10/31/2010 to request information from Principal Investigator.    Top of page A6181030 - Phase II, Open-Label, Non-Randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas   Principal Investigator: Robert Taub   Start date: 04/17/2007 End date: 10/31/2012 to request information from Principal Investigator.    Top of page AMN107 Compassionate Study - Compassionate Use of AMN107 in a Single Patient With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Patient - JD   Principal Investigator: Robert Taub   Start date: 11/08/2007 End date: 05/30/2011 to request information from Principal Investigator.    Top of page AMN107 Compassionate Study - Compassionate Use of AMN107 in a Single Patient With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Patient - JG   Principal Investigator: Robert Taub   Start date: 11/08/2007 End date: 05/30/2013 to request information from Principal Investigator.    Top of page AMN107 Compassionate Study - Compassionate Use of AMN107 in a Single Patient With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST). PATIENT NB   Principal Investigator: Robert Taub   Start date: 11/08/2007 End date: 05/30/2011 to request information from Principal Investigator.    Top of page AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENTContinuation GIST Trial   Principal Investigator: Robert Taub   Start date: 11/02/2007 End date: 05/31/2011 to request information from Principal Investigator.    Top of page AZD6244 - Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda™) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First LIne gemcitabine Therapy (Gemzar)   Principal Investigator: Robert Fine   Start date: 10/18/2006 End date: 04/30/2010 to request information from Principal Investigator.    Top of page Acupuncture for joint pain induced by aromatose inhibitors   Principal Investigator: Katherine Crew   Start date: 01/01/2006 End date: 12/31/2009 to request information from Principal Investigator.    Top of page C15002 - An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Lymphoma or Multiple Myeloma   Principal Investigator: Owen O'Connor   Start date: 07/30/2008 End date: 09/30/2012 to request information from Principal Investigator.    Top of page CA183001 - Phase II study of Intravenous Vinflunine in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium (Study No. CA183001)   Principal Investigator: Daniel P. Petrylak   Start date: 11/29/2005 End date: 05/30/2011 to request information from Principal Investigator.    Top of page CAFE - The CAFE Study - Cancer Patient Fracture Evaluation   Principal Investigator: Gregory Mears   Start date: 03/13/2006 End date: 09/30/2011 to request information from Principal Investigator.    Top of page COMPASSIONATE USE - COMPASSIONATE USE PROTOCOL FOR AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS FOR COLLECTION AND TRANSPLANTATION   Principal Investigator: Ajai Chari   Start date: 11/27/2007 End date: 05/31/2011 to request information from Principal Investigator.    Top of page CRAD001N2201 - CONTRACT-"An open label, single arm, phase II study of RAD001 in patients with refractory mantle cell lymphoma"   Principal Investigator: Owen O'Connor   Start date: 07/07/2008 End date: 10/01/2011 to request information from Principal Investigator.    Top of page Cell-Genesys/GC1940/A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve   Principal Investigator: Daniel P. Petrylak   Start date: 05/11/2006 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Combination Chemotherapy Trial of Gemtuzumab Ogozamicin with Escalating Dose of Mitoxantrone in Patients with AML and High Risk MDS0   Principal Investigator: Gwen Nichols   Start date: 06/18/2002 End date: 06/30/2010 to request information from Principal Investigator.    Top of page D9902B - Randomized, Double Blind, Placebo-Controlled Phase 3 Trial of Immunotherapy with Autologous Antigen presenting Cells Loaded with PA2024 (Provenge, APC8015) in Men with Metastatic Androgen Independent Prostatic Adenocarcin   Principal Investigator: Daniel P. Petrylak   Start date: 01/18/2007 End date: 07/31/2013 to request information from Principal Investigator.    Top of page DFCI ALL Adult Consortium Protocol   Principal Investigator: Jasmine M. Zain   Start date: 09/22/2008 End date: 04/28/2013 to request information from Principal Investigator.    Top of page EFC6668 - Work Order No. 2-Randomized study of Larotaxel + cisplatin (LC) vs. gemcitabine + cisplatin (GC) in the first line treatment of locally advanced/ metastatic urothelial tract and bladder cancer   Principal Investigator: Daniel P. Petrylak   Start date: 05/29/2008 End date: 02/01/2013 to request information from Principal Investigator.    Top of page EXPANDED ACCESS - Expanded access study of plerixafor and G-CSF for the mobilization and collection of peripheral blood stem cell for autologous stem cell transplantation in plants with non-hodkin's lymphoma, hodgkin's disease or multiple myeloma   Principal Investigator: Jasmine M. Zain   Start date: 11/18/2008 End date: 05/30/2012 to request information from Principal Investigator.    Top of page EXPLORE - Examination of PNH by Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes   Principal Investigator: Michael J Flamm   Start date: 04/06/2007 End date: 10/31/2011 to request information from Principal Investigator.    Top of page Enzastaurin - Phase 2 Trial of Oral Enzastaurin in Prostate Cancer Patients who have Rising PSA (1) During Hormonal Manipulation, and (2) after First-Line Cytotoxic Chemotherapy   Principal Investigator: Daniel P. Petrylak   Start date: 04/17/2007 End date: 10/31/2012 to request information from Principal Investigator.    Top of page Extended 39-week Study of PSMA ADC Following the Initial 12-week Dose-Escalation Study in Subjects with Progressive, Castration-Resistant, Metastatic Prostate Cancer.   Principal Investigator: Daniel P. Petrylak   Start date: 09/23/2008 End date: 04/15/2011 to request information from Principal Investigator.    Top of page GIST - PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT®) 37.5 MG DAILY VS IMATINIB]MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) WHO HAVE HAD PROGRESSIVE DISEASE WHILE ON 400   Principal Investigator: Robert Taub   Start date: 10/04/2007 End date: 05/31/2011 to request information from Principal Investigator.    Top of page IRUSANAS0090 - Phase II Study of Glucosamine with Chondroitin on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients.   Principal Investigator: Dawn L Hershman   Start date: 04/10/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Multicenter, Open-Label Single- Arm Study of Yondelis (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment   Principal Investigator: Robert Taub   Start date: 10/04/2006 End date: 04/30/2010 to request information from Principal Investigator.    Top of page Multicenter, randomized, 2-blind, ph3 study of Sunitib plu prednisone versus prednisone in patients with progressive metastatic hormone-refractory prostate cancer after failure of a Docetaxel-based chemotherapy regimen   Principal Investigator: Daniel P. Petrylak   Start date: 11/25/2008 End date: 12/31/2012 to request information from Principal Investigator.    Top of page PB01 - An Open Label, Single Arm Trial of Immunotherapy With Autologous Antigen Presenting Cells Loaded with PA2024 (APC8015F) for Men with Objective Disease Progression on Protocol D9902 Part B   Principal Investigator: Daniel P. Petrylak   Start date: 01/24/2007 End date: 07/31/2011 to request information from Principal Investigator.    Top of page PHASE I/II STUDY OF 10-PROPARGYL-10-DEAZAAMINOPTERIN (PDX) IN RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOPROLIFERATIVE MALIGNANCIES   Principal Investigator: Owen O'Connor   Start date: 04/30/2007 End date: 10/31/2010 to request information from Principal Investigator.    Top of page PILL-2 - Phase I/II Study of the Novel Proteasome Inhibitor Bortezomib in Combination with Rituximab, Cyclophosphamide and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and mantle Cell Lymphoma (MCL)   Principal Investigator: Owen O'Connor   Start date: 09/29/2007 End date: 03/31/2011 to request information from Principal Investigator.    Top of page PSMA ADC 1301: A Phase I Dose-Escalation Study of PSMA ADC in Subjects with Progressive Castration-Resistant Metastatic Prostate Cancer Dose.   Principal Investigator: Daniel P. Petrylak   Start date: 09/23/2008 End date: 04/15/2011 to request information from Principal Investigator.    Top of page PX-171-002 - Phase 1 Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Four Week Cycle (PX-171-002)   Principal Investigator: Owen O'Connor   Start date: 03/10/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Pancreatic Cancer Serum and DNA Repository   Principal Investigator: Robert Fine   Start date: 08/14/2006 End date: 02/28/2011 to request information from Principal Investigator.    Top of page Phase 1 Open-Label Study Evaluating Atrasentan (ABT-627) in combination with Docetaxel and Estramustine in the Treatment of Hormone Refractory Prostate Cancer   Principal Investigator: Daniel P. Petrylak   Start date: 04/08/2005 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Phase 1/2a Open-label Study of Sequential Pralatrexate and Gemcitabine with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Lymphoproliferative Malignancies   Principal Investigator: Owen O'Connor   Start date: 05/03/2007 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Phase 2 Multicenter, Open-labek Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refactory Prostate Cancer (HRPC   Principal Investigator: Daniel P. Petrylak   Start date: 06/14/2007 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Phase 2 Study of Cisplatin + Pemetrexed + Bevacizumab as First-Line Therapy in Patients with Advanced Non-Squamous, Non-Small Cell Lung Carcinoma   Principal Investigator: Mark Stoopler   Start date: 06/11/2007 End date: 12/31/2011 to request information from Principal Investigator.    Top of page Phase 2, Single-Arm, Opoen Label, Multiple center study of CP-751 ,871 in combination with Docetaxel and Prednisone in Patients with Progressive hormone refractory prostate cancer   Principal Investigator: Daniel P. Petrylak   Start date: 07/31/2006 End date: 02/28/2012 to request information from Principal Investigator.    Top of page Phase 2, multicenter, randomized study of IMC-A12 or IMC-1121B plus mitoxantrone and prednisone in metastatic androgen-independent prostate cancer   Principal Investigator: Daniel P. Petrylak   Start date: 10/16/2008 End date: 04/30/2014 to request information from Principal Investigator.    Top of page Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse.   Principal Investigator: Jasmine M. Zain   Start date: 02/04/2008 End date: 08/31/2013 to request information from Principal Investigator.    Top of page Phase 3 Randomized, PC, DB, study of Oral CCI-779 Admin in combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women w/ Locally Advanced or Metastatic Breast Cancer   Principal Investigator: Dawn L Hershman   Start date: 06/30/2004 End date: 10/06/2011 to request information from Principal Investigator.    Top of page Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma   Principal Investigator: Robert Taub   Start date: 10/31/2007 End date: 04/30/2013 to request information from Principal Investigator.    Top of page Phase I Open Label Study of Noscapine (CB3304 ) in Patients with Relapsed or Refractory Multiple Myeloma   Principal Investigator: Jasmine M. Zain   Start date: 01/15/2008 End date: 08/31/2010 to request information from Principal Investigator.    Top of page Phase I Open-Label, Dose Escalation Study to Determine the Maximum Tolerated Dose and to Evaluate the Safety Profile of Lenalidomide (Revlimid CC-5013) with Every Three Week Docetaxel (Taxotere) in Subjects with Androgen Independent Prostate   Principal Investigator: Daniel P. Petrylak   Start date: 08/30/2005 End date: 02/28/2011 to request information from Principal Investigator.    Top of page Phase I Study of Vorinostat in Combination with Niacinamide, and Etoposide for the Treatment of Patients with Relapsed and Refractory Lymphoid Malignancies.   Principal Investigator: Owen O'Connor   Start date: 12/17/2007 End date: 10/31/2012 to request information from Principal Investigator.    Top of page Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Two Week Cycle   Principal Investigator: Owen O'Connor   Start date: 04/26/2007 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Phase I Trial of Alimta (Pemetrexed) plus Taxotere (Doxetaxel) in Advanced Malignancies and Phase II trial of ALimta plus Taxotere in Adnrogen independent metastatic prostate cancer   Principal Investigator: Daniel P. Petrylak   Start date: 05/31/2005 End date: 11/30/2011 to request information from Principal Investigator.    Top of page Phase I-II Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28 Day Cycle in Patients with Non-Hodgkin’s Lymphoma   Principal Investigator: Owen O'Connor   Start date: 04/20/2007 End date: 10/30/2009 to request information from Principal Investigator.    Top of page Phase I/II Trial of Docetaxel, Prednisone, Bevacizumab and Erlotinib in Hormone Refractory Prostate Cancer   Principal Investigator: Daniel P. Petrylak   Start date: 07/26/2006 End date: 01/31/2011 to request information from Principal Investigator.    Top of page Phase I/II study of HKI-272 in combination with vinorelbine in subjects with solid tumors and metastatic breast cancer wyth: HKI272   Principal Investigator: Dawn L Hershman   Start date: 03/17/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression and influence of treatment on Erectile Dysfunction.   Principal Investigator: Katherine Crew   Start date: 08/09/2007 End date: 04/30/2010 to request information from Principal Investigator.    Top of page Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers   Principal Investigator: Robert Fine   Start date: 07/11/2006 End date: 01/31/2012 to request information from Principal Investigator.    Top of page Phase II Study of GW786034 using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma   Principal Investigator: Daniel P. Petrylak   Start date: 04/17/2006 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Phase II study of milataxel (TL139) administered orally in patients with malignant mesothelioma phase II TL139 in patients with mesotherlioma   Principal Investigator: Robert Taub   Start date: 10/16/2008 End date: 04/30/2013 to request information from Principal Investigator.    Top of page Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of romidepsin (depsipeptide, FK228) in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy.   Principal Investigator: Jasmine M. Zain   Start date: 04/15/2008 End date: 04/15/2013 to request information from Principal Investigator.    Top of page Phase II, Randomized, Open-Label, Three-Arm, MC study of MEDI-522, A Humanized Monoclonal Antibody Directed Against teh Human Alpha V Beta 3 Integrin, In Combination with Weekly Docetaxel +/- Low-Dose Estramustine and Zoledronic Acid In the Treatment   Principal Investigator: Daniel P. Petrylak   Start date: 01/19/2005 End date: 07/30/2010 to request information from Principal Investigator.    Top of page Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination with Carboplatin in Patients with Solid Tumors   Principal Investigator: Daniel P. Petrylak   Start date: 10/02/2006 End date: 04/30/2012 to request information from Principal Investigator.    Top of page Poly E MTA - Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-met Signaling and Activation of Pathways Contributing to Breast Cancer Progression   Principal Investigator: Katherine Crew   Start date: 07/18/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Pralatrexate - Phase 1, Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma   Principal Investigator: Jasmine M. Zain   Start date: 07/13/2007 End date: 01/31/2011 to request information from Principal Investigator.    Top of page Randomized Phase II study of docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma   Principal Investigator: Daniel P. Petrylak   Start date: 09/06/2007 End date: 03/31/2013 to request information from Principal Investigator.    Top of page Randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)   Principal Investigator: Robert Fine   Start date: 08/27/2008 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging bone Metastasis-Free Survival in Men with Hormone Refractory Prostate Cancer   Principal Investigator: Daniel P. Petrylak   Start date: 01/14/2008 End date: 10/31/2011 to request information from Principal Investigator.    Top of page Randomized, multicenter, single blind study in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentations of PA2024 antigen   Principal Investigator: Daniel P. Petrylak   Start date: 11/03/2008 End date: 05/13/2013 to request information from Principal Investigator.    Top of page SKI-606 - Phase 2, randomized, OL studyof Bosutinib administered in combo with exemestaine vs. exemestane alone as 2 line therapy in postmenopausal women with locally advanced or metastatic er+pgR+/erb2 Breast cancer   Principal Investigator: Dawn L Hershman   Start date: 02/04/2009 End date: 08/30/2014 to request information from Principal Investigator.    Top of page SUCCEED - Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas.   Principal Investigator: Robert Taub   Start date: 03/15/2008 End date: 03/15/2012 to request information from Principal Investigator.    Top of page Two-arm, non-randomized, multicenter, phase 2 study of VELCADE (bortezomib) in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed follicular lymphoma   Principal Investigator: Owen O'Connor   Start date: 09/26/2008 End date: 02/28/2014 to request information from Principal Investigator.    Top of page VELCADE - 2 Stage, open label, phase 2 study of Velcade plus Eloxatin in previously treated patients with malignant pleural or peritoneal mesotheliona   Principal Investigator: Robert Taub   Start date: 03/06/2009 End date: 09/30/2013 to request information from Principal Investigator.    Top of page VENICE - Multicenter, Randomized, Double-Blind Study comparing the Efficacy and Safety of Flibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer   Principal Investigator: Daniel P. Petrylak   Start date: 01/22/2008 End date: 08/31/2013 to request information from Principal Investigator.    Top of page VINCENT - Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive   Principal Investigator: Daniel P. Petrylak   Start date: 04/23/2007 End date: 10/31/2014 to request information from Principal Investigator.    Top of page Wyeth HKI-272 (2) - Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer.   Principal Investigator: Dawn L Hershman   Start date: 07/25/2007 End date: 03/31/2011 to request information from Principal Investigator.    Top of page entitled A Multi-center Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma, Protocol No. PDX-008   Principal Investigator: Owen O'Connor   Start date: 03/21/2007 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Department : Medicine Division : Infectious Diseases A4001027 HIV1 - MC, RZd, Db, PC trial of a novel CCR5 antagonist , UK 427857 in combination with optimized background therapy vs. optimized background therapy alone for the treatment of antitroviral experienced HIV1 infected subjects   Principal Investigator: Peter Gordon   Start date: 08/27/2008 End date: 12/31/2011 to request information from Principal Investigator.    Top of page PARC'S - PARC'S HIV Elite Controller Study   Principal Investigator: Susan Aileen Olender   Start date: 06/01/2007 End date: 12/30/2012 to request information from Principal Investigator.    Top of page Pfizer EAP - Pfizer HIV Expanded Access Program (EAP) protocol Number A4001050   Principal Investigator: Peter Gordon   Start date: 05/21/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Raltegravir - Phase III open label single arm study to evaluate the safety. tolerability and efficacy of MK-0518/Raltegravir i a diverse cohort of HIV infected patients.   Principal Investigator: Michael T. Yin   Start date: 02/25/2009 End date: 08/31/2010 to request information from Principal Investigator.    Top of page Department : Medicine Division : Medical Oncology Phase II Study of AVN944 in Combination with Gemcitabine For the Treatment of Pancreatic Cancer   Principal Investigator: Michael John Hall   Website: Start date: 06/13/2008 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Department : Medicine Division : Nephrology **STUDY MANAGER** A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease   Principal Investigator: Jai Radhakrishnan   Start date: 11/06/2007 End date: 05/30/2012 to request information from Principal Investigator.    Top of page **STUDY MANAGER** A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 For Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment   Principal Investigator: Leonard Stern   Start date: 01/29/2009 End date: 06/30/2013 to request information from Principal Investigator.    Top of page AEB - 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus in combination with myfortic®, Simulect® and corticosteroids in de novo adult rena   Principal Investigator: David J. Cohen   Start date: 01/17/2008 End date: 07/31/2010 to request information from Principal Investigator.    Top of page ALMS - Prospective, Rzd, Db, Act- cont, PG, MC trial to assess the efficacy and safety of mycophenolate mofetil in maintaining remission and renal functioin in subjects with lupus nephritis who underwent induction therapy with either MMF or Cyclophosphami   Principal Investigator: Gerald B. Appel   Start date: 11/11/2005 End date: 05/31/2010 to request information from Principal Investigator.    Top of page BELONG - Randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of two doses of ocrelizumab in patients with WHO or ISN Class III or IV nephritis due to systematic lupus erythematosus   Principal Investigator: Gerald B. Appel   Start date: 11/13/2008 End date: 05/31/2014 to request information from Principal Investigator.    Top of page Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease.   Principal Investigator: Thomas Nickolas   Start date: 07/23/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page CORAL - Cardiovascular Outcome in Renal Atherosclerotic Lesions Randomized & Multicenter Two Group Clinical Trial to Assess the Best Treatment for Patients with High Blood Pressure & Renal Artery Stenosis   Principal Investigator: Gerald B. Appel   Start date: 05/17/2006 End date: 03/31/2010 to request information from Principal Investigator.    Top of page Collaborative study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy   Principal Investigator: Cheryl Lynne Kunis   Start date: 04/11/2006 End date: 10/31/2010 to request information from Principal Investigator.    Top of page LCP tacro 2017 - Phase 2,Open label, mc, randomized trail to demostrate the pharmacokinetics of LCP-tacro tablets 2 daily and Prograf capsules 2 day in adult de novo kindney transplant patients   Principal Investigator: David J. Cohen   Start date: 11/12/2008 End date: 05/31/2014 to request information from Principal Investigator.    Top of page Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with ISN/RPS Class III of IV Lupus Nephritis   Principal Investigator: Gerald B. Appel   Start date: 03/23/2006 End date: 12/31/2010 to request information from Principal Investigator.    Top of page SHPT registry - SHPT Registry- Chronic Kidney Disease Subjects on Dialysis with Secondary Hyperparathyroidism   Principal Investigator: Leonard Stern   Start date: 04/22/2005 End date: 10/31/2012 to request information from Principal Investigator.    Top of page Department : Medicine Division : Preventive Medicine & Nutrition RADICHOL II - RADICHOL II: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects with Coronary Artery Disease   Principal Investigator: Henry N. Ginsberg   Start date: 10/14/2008 End date: 04/30/2011 to request information from Principal Investigator.    Top of page Department : Medicine Division : Pulmonary Cardiology IGIV for Lung Transplant - IGIV For Acquired Immunodeficiency in Lung Transplant Patients   Principal Investigator: Selim Arcasoy   Start date: 03/31/2005 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in ...   Principal Investigator: Selim Arcasoy   Start date: 11/25/2008 End date: 05/31/2013 to request information from Principal Investigator.    Top of page Department : Medicine Division : Pulmonary, Allergy & Critical Care Medicine ARTEMIS - ARTEMIS: A phase 3, randomized 2-blind, placebo-controlled, mc, parallel group, event driven study to evaluate the efficacy and safety of Ambrisentan in subjects with early idiopathic pulmonary fibrosis (IPF)   Principal Investigator: David J. Lederer   Start date: 01/29/2009 End date: 07/30/2013 to request information from Principal Investigator.    Top of page Airway Gene Expression in the Diagnosis of Lung Cancer   Principal Investigator: Charles Powell   Start date: 01/12/2009 End date: 07/31/2010 to request information from Principal Investigator.    Top of page An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies.   Principal Investigator: Nina Patel   Start date: 07/02/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Bronchiectasis Research Registry   Principal Investigator: Byron Thomashow   Start date: 10/28/2008 End date: 04/30/2014 to request information from Principal Investigator.    Top of page Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension   Principal Investigator: Steven M. Kawut   Start date: 03/01/2006 End date: 02/28/2011 to request information from Principal Investigator.    Top of page Double-blind, randomized, placebo-controlled study to evaluate the safety, pharmacokinetics, and efficacy of IMA-638 in subjects with persistent asthma   Principal Investigator: Emily DiMango   Start date: 01/25/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page EASE TRIAL - Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects with Severe Hyperinflation   Principal Investigator: Roger Maxfield   Start date: 01/24/2007 End date: 07/31/2012 to request information from Principal Investigator.    Top of page TIGER - 2 - Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV1 > 75% Predicted   Principal Investigator: Emily DiMango   Start date: 05/13/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Tuberculosis Trials Consortium   Principal Investigator: Neil W Schluger   Start date: 09/23/1999 End date: 09/22/2009 to request information from Principal Investigator.    Top of page Department : Medicine Division : Rheumatology ABATACEPT - Phase IIB, Multi-Center, Rzd, DB, Pc Study to Evaluate the Efficacy and Safety of Abatacept vs. Placebo on a Background of Oral Glucocorticosteroids in the Tnt of Sjts with Systemic Lupus Erythematosus and the prevention of subsequent lupus fl   Principal Investigator: Meggan Mackay   Start date: 05/25/2006 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Mechanism of action-Rituximab in SLE   Principal Investigator: Betty Diamond   Start date: 01/25/2007 End date: 07/31/2010 to request information from Principal Investigator.    Top of page Randomized, parallel, double-blind, placebo-controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in subjects wtih active seropositive rheumatoid arthritis on a background of methotrexate   Principal Investigator: Edward Dwyer   Start date: 05/01/2008 End date: 10/30/2010 to request information from Principal Investigator.    Top of page Department : Neurological Surgery Division : Epilepsy Movement Clinical Evaluation For The Management of Patients With Single or Recurrent Major Depressive Disorder With Deep Brain Stimulation.   Principal Investigator: Robert R Goodman   Start date: 04/10/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Department : Neurological Surgery Division : Neuro Surgeon Multicenter Study of Non-invasive Intracranial Pressure   Principal Investigator: Sander E. Connolly   Start date: 03/16/2007 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Department : Neurological Surgery Division : Neurooncology Prospective Multi-Center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients with Progressive or Recurrent GBM   Principal Investigator: Jeffrey N Bruce   Start date: 11/17/2006 End date: 05/31/2010 to request information from Principal Investigator.    Top of page Department : Neurological Surgery Division : Spine Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair with Standard of Care Methods during Spinal Surgery   Principal Investigator: Paul McCormick   Start date: 05/24/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Prospective, Multi-Center, Randomized Controlled Study to comapre the Spinal Sealant System as an Adjunct to Sutured Dural Repair with Standard of Care Methods during Spinal Surgery.   Principal Investigator: Michael Kaiser   Start date: 01/12/2006 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Prospective, Randomized Clinical Investigation of the SECURE-C Cervical Artificial Disc: A Pivotal Study   Principal Investigator: Michael Kaiser   Start date: 03/22/2006 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Department : Neurology Division : Dementia and Aging Effect of Gamma-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo.   Principal Investigator: Lawrence S. Honig   Start date: 08/14/2008 End date: 03/31/2013 to request information from Principal Investigator.    Top of page Elan - 301 - ELN115727-301: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein   Principal Investigator: Lawrence S. Honig   Start date: 04/28/2008 End date: 07/31/2011 to request information from Principal Investigator.    Top of page Elan 302 - ELN115727-301: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E   Principal Investigator: Lawrence S. Honig   Start date: 04/28/2008 End date: 07/31/2011 to request information from Principal Investigator.    Top of page Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer's Type   Principal Investigator: Lawrence S. Honig   Start date: 05/05/2007 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s Disease.   Principal Investigator: Lawrence S. Honig   Start date: 04/28/2008 End date: 10/31/2013 to request information from Principal Investigator.    Top of page Department : Neurology Division : Epilepsy An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures   Principal Investigator: Derek Chong   Start date: 08/23/2007 End date: 02/28/2018 to request information from Principal Investigator.    Top of page An Open-Label extension trial to determine tolerabiltiy and efficacy of long term oral SPM 927 as adjunctive therapy in pateints with partial seizures   Principal Investigator: Derek Chong   Start date: 04/16/2003 End date: 09/18/2009 to request information from Principal Investigator.    Top of page Eszopiclone for Insomnia in Epilepsy   Principal Investigator: Carl Bazil   Start date: 10/26/2007 End date: 04/30/2011 to request information from Principal Investigator.    Top of page IN Clonazepam - Phase IIa, Open-Label, Proof-of-Concept Study to Evaluate the Efficacy and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures.   Principal Investigator: Lawrence J. Hirsch   Start date: 04/10/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page RNS - Responsive Neurostimulator System Pivotal Clinical Investigation   Principal Investigator: Lawrence J. Hirsch   Start date: 12/08/2006 End date: 05/31/2010 to request information from Principal Investigator.    Top of page Responsive Neurostimulator (RNS) System Long-term Treatment Clinical Investigation   Principal Investigator: Lawrence J. Hirsch   Start date: 06/20/2006 End date: 12/31/2014 to request information from Principal Investigator.    Top of page Rufinamide - Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures   Principal Investigator: Derek Chong   Start date: 01/10/2007 End date: 06/30/2012 to request information from Principal Investigator.    Top of page Department : Neurology Division : G H Sergievsky Center 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study with mild Alzheimer's disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106   Principal Investigator: Karen Bell   Start date: 12/12/2008 End date: 06/30/2011 to request information from Principal Investigator.    Top of page AAB-001 - MC, randomized, 2-blind, placebo-controlled, multiple ascending dose safety,tolerability, reactogenicity and pharmacokinetic study of Bapineuzumab (AAB-001) administered subcutaneously in subjects with Mild to Moderate Alzheimer Disease   Principal Investigator: Karen Bell   Start date: 03/11/2008 End date: 09/30/2011 to request information from Principal Investigator.    Top of page Memantine in FTD - Prospective, Randomized, Multi-Center, Double-Blind 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia.   Principal Investigator: Karen Bell   Start date: 07/08/2008 End date: 06/30/2010 to request information from Principal Investigator.    Top of page TPA010RI - 2-blind, placebo-controlled, randomized MC studyevaluating the efficacy and safety of 18 mos. of treatment with PF 04494700 (TTP488) in participants with mild to moderate Alzheimer's Disease   Principal Investigator: Karen Bell   Start date: 08/22/2007 End date: 12/10/2011 to request information from Principal Investigator.    Top of page Wyeth ACC-001 in AD - Phase IIa, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability and Immunogenicity Trial of ACC-001 With QS-21 Adjuvant in Patients With Mild to Moderate Alzheimer's Disea   Principal Investigator: Karen Bell   Start date: 10/19/2007 End date: 05/30/2011 to request information from Principal Investigator.    Top of page Wyeth SAM-531 in AD - Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects with Mild to Moderate Alzheimer's Disease.   Principal Investigator: Karen Bell   Start date: 07/30/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Department : Neurology Division : General Neurology CASSCO - CLOPIDROGREL AND ASPIRIN IN REDUCTION OF CAROTID THICKNESS AND STIFFNESS AFTER STROKE (CASS) TRIAL: Cognitive Outcomes   Principal Investigator: Joanne Festa   Start date: 12/06/2005 End date: 12/31/2010 to request information from Principal Investigator.    Top of page Post-Approval Study (PAS) To Monitor the Clinical Performance of the AbioCor%AE in Severe End-Stage Heart Disease Patients.   Principal Investigator: Joanne Festa   Start date: 04/18/2008 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Department : Neurology Division : Movement Disorders MIRAPEX - Two year open label, randomized, parallel group, bliinded assessment opthalmologic safety study of pramipexole IR vs ropinirole in early Parkinson's disease patients   Principal Investigator: Cheryl Waters   Start date: 07/08/2005 End date: 10/21/2009 to request information from Principal Investigator.    Top of page Patch 921 - Multicenter, randomized, double-blind, placebo-controlled, 5-arm, parellel-group trial to assess rotigotine transdermal system dose response in subjects with advanced-stage Parkinson's disease   Principal Investigator: Cheryl Waters   Start date: 12/04/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Solvay Open-Label (DuoDopa) - Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations.   Principal Investigator: Cheryl Waters   Start date: 06/13/2008 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Department : Neurology Division : Movement Disorders/neuromuscular Two Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients with Amyotrophic Lateral Sclerosis (ALS).   Principal Investigator: Jinsy Andrews   Start date: 05/05/2008 End date: 11/30/2010 to request information from Principal Investigator.    Top of page Department : Neurology Division : Multiple Sclerosis and Demyelinating Diseases MAESTRO-03 - Double-Blind, Placebo Controlled Multi-Center Study to evaluate the efficacy and Safety of MBP8298 in subjects with secondary progressive Multiple Sclerosis   Principal Investigator: Mark Tullman   Start date: 10/04/2007 End date: 04/30/2011 to request information from Principal Investigator.    Top of page MAESTRO-03 - SUB-STUDY: A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 on Visual Function Testing ...in Subjects with Secondary Progressive Multiple Sclerosis   Principal Investigator: Mark Tullman   Start date: 07/07/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page OCRELIZUMAB - Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex® controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with   Principal Investigator: Mark Tullman   Start date: 01/20/2009 End date: 06/30/2014 to request information from Principal Investigator.    Top of page OPEN LABEL STUDY OF SAFETY AND TOLERABILITY OF RITUXIMAB© IN NEUROMYELITIS OPTICA, RECURRENT TRANSVERSE MYELITIS AND RECURRENT BILATERAL SIMULTANEOUS OPTIC NEURITIS   Principal Investigator: Mark Tullman   Start date: 04/02/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Department : Neurology Division : Neuromuscular Disease B for SMA - Pilot Study of Biomarkers for SMA   Principal Investigator: Petra Kaufmann   Start date: 11/26/2008 End date: 05/30/2010 to request information from Principal Investigator.    Top of page DMQ and ALS (07-AVR-123) - Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect   Principal Investigator: Hiroshi Mitsumoto   Start date: 03/27/2008 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Exercise Testing and A3243G - Exercise Testing in A3243G Mitochondrial Carrier Relatives.   Principal Investigator: Petra Kaufmann   Start date: 01/09/2008 End date: 07/31/2011 to request information from Principal Investigator.    Top of page Phase 2b Efficacy and Safety Study jof PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy.   Principal Investigator: Petra Kaufmann   Start date: 06/30/2008 End date: 12/31/2010 to request information from Principal Investigator.    Top of page TALAMPANEL ALS - Talampanel ALS-201   Principal Investigator: Hiroshi Mitsumoto   Start date: 09/25/2008 End date: 09/01/2010 to request information from Principal Investigator.    Top of page Department : Neurology Division : Neurooncology **STUDY MANAGER** A Phase I/II Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnozed Glioblastoma Multiforme   Principal Investigator: Rose Lai   Start date: 04/26/2007 End date: 10/31/2009 to request information from Principal Investigator.    Top of page ANG1005-CLN-01 - Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Malignant Glioma.   Principal Investigator: Steven Rosenfeld   Start date: 11/01/2007 End date: 05/31/2010 to request information from Principal Investigator.    Top of page ANG1005-CLN-02 - Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Advanced Solid Tumors and Metastatic Brain Cancer.   Principal Investigator: Steven Rosenfeld   Website: angiochem.com Start date: 11/01/2007 End date: 05/31/2010 to request information from Principal Investigator.    Top of page An open-label, multi-center, Phase II study to evaluate the activity of Patupilone (EPO906) in the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer.   Principal Investigator: Steven Rosenfeld   Start date: 04/28/2006 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Gliogene - Gliogene: An International Consortium to identify susceptibility genes in high-risk familial glioma pedigrees   Principal Investigator: Rose Lai   Start date: 01/07/2008 End date: 07/31/2013 to request information from Principal Investigator.    Top of page PCNSL - PCNSL: A Pilot Study of combined Immunochemotherapy Followed by Reduced Dose RT for Patients with Newly Diagnosed PCNSL   Principal Investigator: Rose Lai   Start date: 07/18/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Phase I/II BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma   Principal Investigator: Rose Lai   Start date: 10/30/2008 End date: 04/30/2011 to request information from Principal Investigator.    Top of page RECENTIN(tm) - AstraZeneca: A Phase III, Randomised,Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171 [RECENTIN(tm)] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomust   Principal Investigator: Steven Rosenfeld   Start date: 12/02/2008 End date: 12/02/2011 to request information from Principal Investigator.    Top of page TM 601-007 - Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MR Imaging Criteria in Patients with Progressive and/or Recurrent Malignant Glioma   Principal Investigator: Steven Rosenfeld   Start date: 01/31/2008 End date: 08/31/2013 to request information from Principal Investigator.    Top of page TMI Study - **STUDY MANAGER** A PHASE II OPEN-LABEL, MULTIPLE-DOSE STUDY OF INTRACAVITARY ADMINISTERED 131I-TM-601 IN ADULT PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA   Principal Investigator: Steven Rosenfeld   Start date: 05/07/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Department : Neurology Division : Stroke and Critical Care ACCELERATE - The evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment.   Principal Investigator: Kiwon Lee   Start date: 05/20/2008 End date: 11/30/2009 to request information from Principal Investigator.    Top of page ARUBA - Clinical Trial of Unruptured Brain AVMS-Yr1   Principal Investigator: Jay P Mohr   Website: Start date: 01/01/2006 End date: . to request information from Principal Investigator.    Top of page COSS - COSS   Principal Investigator: Randolph S. Marshall   Start date: 12/01/2007 End date: 11/30/2012 to request information from Principal Investigator.    Top of page RECON - RECON: STUDY OF CAROTID OCCLUSION AND NEUROCOGNITION   Principal Investigator: Randolph S. Marshall   Start date: 12/01/2004 End date: 11/30/2009 to request information from Principal Investigator.    Top of page SPS3 - Secondary Prevention of Small SubCordical Strokes (SPS3)   Principal Investigator: Mitchell S. Elkind   Start date: 03/01/2003 End date: 06/30/2011 to request information from Principal Investigator.    Top of page STAT Data registry - Studying the Treatment of Acute Hypertension   Principal Investigator: Neeraj Badjatia   Start date: 12/10/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Department : Obstetrics and Gynecology Division : Family Planning & Preventive Services CCTN - HHSN275200403374I - NICHD Contraceptive Clinicals Network (Female Clinical Trial Topic Area) Yr 1   Principal Investigator: Carolyn L. Westhoff   Start date: 04/01/2004 End date: 03/31/2011 to request information from Principal Investigator.    Top of page Feasibility and Acceptability of the Pantarhei Sampler for Cervical Cytology in Low Income Women in New York City   Principal Investigator: Carolyn L. Westhoff   Start date: 09/30/2008 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Obstetrics and Gynecology Division : Gynecologic Oncology An open-label multi-center randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS™ with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer   Principal Investigator: Thomas Herzog   Start date: 01/19/2006 End date: 01/31/2010 to request information from Principal Investigator.    Top of page ChemoFx Registry - An observational, longitudinal, multi-center study examining outcomes associated with the use of the ChemoFx Assay in solid tumor malignancies   Principal Investigator: Thomas Herzog   Start date: 08/29/2007 End date: 02/28/2012 to request information from Principal Investigator.    Top of page Oceans Study - Phase II, multicenter, randmoized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma   Principal Investigator: Thomas Herzog   Start date: 07/18/2007 End date: 01/31/2013 to request information from Principal Investigator.    Top of page PILOT PHASE II STUDY EVALUATING THE COMBINATION OF OXALIPLATIN AND DOCETAXEL WITH BEVACIZUMAB AS FIRST LINE THERAPY IN PATIENTS WITH FIGO STAGE IB-IV EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CARCINOMA   Principal Investigator: Thomas Herzog   Start date: 08/25/2006 End date: 02/28/2017 to request information from Principal Investigator.    Top of page SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE TRIFUNCTIONAL ANTIBODY CATUMAXOMAB (ANTI-EPCAM × ANTI-CD3)ADMINISTERED INTRAPERITONEALLY IN OVARIAN CANCER PATIENTS WITH RECURRENT SYMPTOMATIC MALIGNANT ASCITES   Principal Investigator: Thomas Herzog   Start date: 08/01/2006 End date: 02/28/2016 to request information from Principal Investigator.    Top of page Department : Obstetrics and Gynecology Division : Maternal Fetal Medicine Maternal Fetal Medicine Unit Network at CUMC   Principal Investigator: Ronald J. Wapner   Start date: 04/01/2006 End date: 03/31/2011 to request information from Principal Investigator.    Top of page Department : Obstetrics and Gynecology Division : Menopause MP   Principal Investigator: Michelle P. Warren   Start date: 10/08/2008 End date: 10/30/2010 to request information from Principal Investigator.    Top of page Multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD on bone turnover markers   Principal Investigator: Michelle P. Warren   Start date: 07/10/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page Department : Obstetrics and Gynecology Division : Obstetrics and Gynecology Antepartum Interpersonal Psychotherapy at 3 NYC Sites - Yr 1   Principal Investigator: Jane Cleary-Goldman   Start date: 09/21/2005 End date: 05/31/2010 to request information from Principal Investigator.    Top of page Prospective, Controlled, Randomized, Multi-Center, Phase I/II Study Evaluating the Safety and Efficacy of Adhexil   Principal Investigator: Melvin Thornton   Start date: 10/23/2007 End date: 05/30/2010 to request information from Principal Investigator.    Top of page Department : Obstetrics and Gynecology Division : Reproduction and Endocrinology DVS SR - Double-blind, randomized, placebo-controlled study assessing the safety and efficacy of DVS SR for the treament of vasomotor symptoms associated with menopause.   Principal Investigator: Rogerio A. Lobo   Start date: 05/14/2008 End date: 05/13/2010 to request information from Principal Investigator.    Top of page KEEPS - Effects of estrogen replacement on atherosclerosis progression in recently menopausal women   Principal Investigator: Rogerio A. Lobo   Start date: 11/01/2004 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Department : Ophthalmology Division : Glaucoma XALATAN - Phase I, Open lable study of latanoprost acid plasma concentrations in pediatric and adult glaucoma patients treated with latanoporst 0.005%   Principal Investigator: Lama Al-Aswad   Start date: 01/22/2009 End date: 07/31/2010 to request information from Principal Investigator.    Top of page Department : Ophthalmology Division : Macula Surgical & Medical Retinal Disease BRAVO - Phase III Multicenter, Randomized, Sham Injection -Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion   Principal Investigator: Gaetano Barile   Start date: 08/09/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page CRUISE - PHASE III, MULTICENTER, RANDOMIZED, SHAM INJECTION%96CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION COMPARED WITH SHAM IN SUBJECTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION   Principal Investigator: Gaetano Barile   Start date: 08/21/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page GENEN - OL, MC extension sty. to eval the saf and toler of Ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a genentech sponsored ranibizumab stud   Principal Investigator: Gaetano Barile   Start date: 09/16/2005 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Ophthalmology Division : Ophthalmology CORNEAL ECTASIA - Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Corneal Ectasia after Refractive Surgery.   Principal Investigator: Stephen Trokel   Start date: 06/21/2008 End date: 06/16/2010 to request information from Principal Investigator.    Top of page UVX Illumination System - Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus.   Principal Investigator: Stephen Trokel   Start date: 06/17/2008 End date: 06/16/2010 to request information from Principal Investigator.    Top of page Department : Ophthalmology Division : Other CLEAR-IT 3 - Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (CLEAR-IT 3), Protocol VGFT-OD-06   Principal Investigator: Stanley Chang   Start date: 09/18/2007 End date: 03/31/2011 to request information from Principal Investigator.    Top of page Randomized, placebo controlled, 2-masked, mc trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion.   Principal Investigator: Stanley Chang   Start date: 02/02/2009 End date: 07/31/2010 to request information from Principal Investigator.    Top of page Department : Orthopedic Surgery Division : Lower Extremity and Reconstruction GEM OS1 For Ankle Fusion - Prospective, randomized, controlled, pivotal human clinical trial to evaluate the safety and effectiveness of GEM OS1 compared to autologous bone graft as a bone regeneration device in foot and ankle fusions.   Principal Investigator: Justin Greisberg   Start date: 03/27/2008 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Wright Medical Ceramic-on-Metal Total Hip Arthroplasty IDE Study   Principal Investigator: William B. Macaulay   Start date: 11/20/2008 End date: 05/31/2011 to request information from Principal Investigator.    Top of page rhBMP-2/CPM - Phase 2, MC, randomized, active controlled parallel group dose finding and safety study of recombinant human bone morphogenetic protein in subjects with decreased bone mineral density   Principal Investigator: William B. Macaulay   Start date: 11/21/2008 End date: 05/31/2014 to request information from Principal Investigator.    Top of page Department : Otolaryngology/head and Neck Surgery Division : Head & Neck Surgery Evaluation of music benefits in adults with HiResolution Fidelity 120 sound processing music benefits in HighRes 120   Principal Investigator: Jaclyn B. Spitzer   Start date: 11/18/2008 End date: 05/30/2011 to request information from Principal Investigator.    Top of page Department : Pathology Division : Hemopathology Safety and Effectiveness in a Multi-Center Randomized, Sham-Controlled Investigation for Dry, Non-Exudative Age Related Macular Degeneration Using Rheopheresis   Principal Investigator: Joseph Schwartz   Start date: 08/20/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Autoimmune & Molecular Diseases MDX-1342 - A Phase 1, Single-blind, Randomized, Placebo-controlled, Multicenter, Single-dose, Dose-escalation Safety & Tolerability Study of MDX-1342 in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis   Principal Investigator: Robert Winchester   Start date: 04/21/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Cardiology AGA Closure of ventricular septal defects with the amplatzer muscular VSD occluder   Principal Investigator: William E. Hellenbrand   Start date: 10/21/2008 End date: 04/30/2014 to request information from Principal Investigator.    Top of page ARIES-3 - Phase 3. Lomg-term, Open-label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects with Pulmonary Hypertension.   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 01/25/2007 End date: 07/31/2010 to request information from Principal Investigator.    Top of page ASD PMS II - Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder Post Market Study   Principal Investigator: William E. Hellenbrand   Start date: 06/20/2008 End date: 08/31/2011 to request information from Principal Investigator.    Top of page ASSET 3 - Long-term, open-label, multicenter extension study of bosentan in patients with pulmonary hypertension associated with sickle cell disease completing a double-blind ASSET study   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 03/14/2007 End date: 09/30/2010 to request information from Principal Investigator.    Top of page COAST - Coarctation of the Aorta Stent Trial (COAST)   Principal Investigator: William E. Hellenbrand   Start date: 04/16/2008 End date: 06/30/2014 to request information from Principal Investigator.    Top of page COMPASS 3 - An Open-label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling   Principal Investigator: Robyn J. Barst   Start date: 06/12/2007 End date: 12/31/2010 to request information from Principal Investigator.    Top of page Cardiolite 301 - Phase III, open-label, non-randomized, international multicenter trial to evaluate the efficacy and safety of cardiolite myocardial perfusion imaging in pediatric subjects with kawasaki disease   Principal Investigator: Ashwin Prakash   Start date: 01/17/2006 End date: 07/31/2017 to request information from Principal Investigator.    Top of page Gleevec - Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 6 months of treatment with tyrosine kinase inhibitor STI571 for the treatment of pulmonary arterial hypertension.   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 08/17/2007 End date: 02/28/2011 to request information from Principal Investigator.    Top of page MEDTRON - Chronicle Implantable Hemodynamic Monitoring System Pulmonary Arterial Hypertension Pilot Study   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 03/29/2004 End date: 06/30/2010 to request information from Principal Investigator.    Top of page MELODY - Implantation of the Medtronic Transcatheter Pulmonary Valve in Patients wiht Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Feasibility Study   Principal Investigator: William E. Hellenbrand   Start date: 03/26/2007 End date: 09/30/2011 to request information from Principal Investigator.    Top of page Method for Evaluating and Improving Outcomes in Pediatric Cardiac Catheterizations   Principal Investigator: William E. Hellenbrand   Start date: 01/23/2007 End date: 07/31/2011 to request information from Principal Investigator.    Top of page PFIZER - Continuation Study of Sildenafil and Flolan when used in combination   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 06/30/2003 End date: 06/30/2010 to request information from Principal Investigator.    Top of page PHIRST - An Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 12/23/2005 End date: 06/30/2010 to request information from Principal Investigator.    Top of page REVEAL Registry - Registry to Evaluate Early and Long-term PAH Disease Management   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 10/12/2006 End date: 04/30/2014 to request information from Principal Investigator.    Top of page SERAPHIN - Study with endothelin receptor antagonist in pulmonary arterial hypertension to improve clinical outcome   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 02/03/2009 End date: 08/31/2011 to request information from Principal Investigator.    Top of page pfizer - MC Long Term Extension Study to Assess the Safety of Oral Sildenafil in the Treatment of Subjects who have completed study 1131   Principal Investigator: Robyn J. Barst   Start date: 01/23/2004 End date: 06/30/2010 to request information from Principal Investigator.    Top of page seraphin ol - Long term single arm OL extension study of the Seraphin Stuy to assess the safety and tolerability of ACT 064992 in patients with symptomatic pu,onary arterial hypertension   Principal Investigator: Erika S. Berman-Rosenzweig   Start date: 02/03/2009 End date: 08/31/2015 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Endocrinology Post Marketing Surveillance program for Protropin (Somatrem for injection) and Nutropin (Somatropin for injection)   Principal Investigator: Sharon Oberfield   Start date: 07/01/1994 End date: 12/31/2011 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Gastroenterology & Nutrition ALF PEDS - U01 DK072146/A Multi-Center Group to Study Acute Liver Failure in Children   Principal Investigator: Steven J. Lobritto   Start date: 09/01/2005 End date: 08/31/2010 to request information from Principal Investigator.    Top of page Phase 3 double-Blind, Randomized, Placebo-Controlled Study of the Safety adn Efficacy of Adefovir Dipivoxil in Children and Adolescents with Chronic Hepatitis B   Principal Investigator: Steven J. Lobritto   Start date: 10/14/2004 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Hematology and Blood and Marrow Transplant Clofarabine in Combination with Cytarabine and Total Body Irradiation Followed by Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia and Acute Non-Lymphoblastic Leukemia in Third Complete Remission   Principal Investigator: Mitchell S. Cairo   Start date: 05/30/2007 End date: 11/30/2009 to request information from Principal Investigator.    Top of page SUBCONTRACT for Clofarabine in combination with cytarabine and total body irradiation followed by allogeneic stem cell transplantation in children with acute lymphoblastic leukemia and acute non-lymphoblastic leukemia in third complete remission.   Principal Investigator: Mitchell S. Cairo   Start date: 12/02/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Infectious Diseases 2304 - MC, OL, SA, 2-step study to evaluate the safety and single dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediatric formulation to children 1-12 years of age with Herpes simplex infection   Principal Investigator: Natalie Neu   Start date: 05/27/2005 End date: 11/30/2009 to request information from Principal Investigator.    Top of page HPV Vaccine - Study to Evaluate the efficacy of Quadrivalent HPV (Types 6, 11, 16, & 18) L1 virus-like particle in reducing the incidence of HPV 6-,11-,16-, &18 related genital warts, & the Incidence of HPV & related Genital Infection in 16-23 years   Principal Investigator: Natalie Neu   Start date: 04/19/2005 End date: 10/31/2009 to request information from Principal Investigator.    Top of page Tygacil in PEDS - Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections   Principal Investigator: Natalie Neu   Start date: 10/05/2007 End date: 05/31/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Neonatology & Perinatal Medicine Long Term Follow Up After Head Cooling For Neonatal Encephalopathy Abbreviated Title: Brain Cooling Long Term Follow Up   Principal Investigator: Richard A Polin   Start date: 01/04/2008 End date: 07/31/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Oncology Phase 1/Phase 2 Study of CP-751,871 in Patients With Relapsed and/or Refractory Ewings Sarcoma Family of Tumors. Abbreviated Title: Pfizer: A4021020-1018   Principal Investigator: Linda Granowetter   Start date: 07/31/2007 End date: 07/31/2012 to request information from Principal Investigator.    Top of page Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors   Principal Investigator: Julia Glade-Bender   Start date: 07/28/2007 End date: 01/31/2010 to request information from Principal Investigator.    Top of page RASALL - Study of rasburicase treatment for chemotherapy or malignancy-induced hyperuricemia in patients with a history of asthma or allergies   Principal Investigator: Kara Kelly   Start date: 10/13/2008 End date: 03/31/2012 to request information from Principal Investigator.    Top of page Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia   Principal Investigator: Julia Glade-Bender   Start date: 01/16/2008 End date: 07/31/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Pulmonary Inner-City Anti-IgE Therapy for Asthma (ICATA)   Principal Investigator: Meyer Kattan   Start date: 09/18/2007 End date: 03/31/2010 to request information from Principal Investigator.    Top of page Department : Pediatrics Division : Rheumatology APPLE - The Atherosclerosis Prevention in Pediatric Lupus Erythematosus   Principal Investigator: Lisa Imundo   Start date: 12/01/2003 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Department : Psychiatry Division : Behavioral Medicine OLZ and Task Engagement - Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia.   Principal Investigator: Jimmy Choi   Start date: 03/20/2008 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Department : Psychiatry Division : Child Psychiatry DVSSR3151A62000 - Multicenter, open-label, safety, tolerability and pharmacokinetic study to evaluate single ascending doses and subsequent short-term administration of fixed doses of desvenlafaxine...   Principal Investigator: Moira A Rynn   Start date: 03/15/2008 End date: 05/19/2010 to request information from Principal Investigator.    Top of page Department : Psychiatry Division : Geriatrics Multi-center, open-label study in healthy 55-80 year old volunteers and patients with affective and anxiety disorders to characterize the regional distribution of [11C] ABP-688 in brain by positron emission tomography (PET)   Principal Investigator: Devangere P. Devanand   Start date: 06/05/2007 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Psychiatry Division : Neuroscience PET Evaluation of Serotonin and Dopamine Transporter Occupancy Associated with Oral Administration of Single Doses of SEP-225289 to Healthy Volunteers   Principal Investigator: Ramin Parsey   Start date: 12/07/2007 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Department : Psychiatry Division : Other Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects with Acute Exacerbations of Schizophrenia   Principal Investigator: Jeffrey A. Lieberman   Start date: 10/18/2007 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Department : Psychiatry Division : Substance Abuse Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence   Principal Investigator: Maria A. Sullivan   Start date: 10/03/2007 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Department : Radiation Oncology Division : Radiation Oncology Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Can   Principal Investigator: Peter Schiff   Start date: 05/24/2006 End date: 11/30/2015 to request information from Principal Investigator.    Top of page Department : Radiology Division : Interventional Radiology RENAISSANCE - Prospective Multicenter Single Arm Study Evaluating the Express Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium   Principal Investigator: Ziv J. Haskal   Start date: 07/14/2004 End date: 03/31/2010 to request information from Principal Investigator.    Top of page REX VENA CAVA FILTER - DEVICE STUDY: Rex Medical Option Vena Cava Filter Clinical Trial   Principal Investigator: Ziv J. Haskal   Start date: 07/18/2007 End date: 01/31/2013 to request information from Principal Investigator.    Top of page Department : Radiology Division : Neurosurgery CARNEROS 1 - Phase 2, MC, Open Label, Two Stage Study to Evaluate the Saftey and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Funtion and Rapid Opening of Arteries in Stroke   Principal Investigator: Philip M. Meyers   Start date: 12/05/2007 End date: 06/30/2013 to request information from Principal Investigator.    Top of page Evaluation of the Penumbra Stroke System in the Revascularization of Patients with Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease   Principal Investigator: Philip M. Meyers   Start date: 01/09/2007 End date: 07/31/2012 to request information from Principal Investigator.    Top of page Department : School Of Dental and Oral Surgury Division : Periodontics Phase 2B Trial of Transmucosal Herbal Periodontal Patch in Subjects With Gingivitis.   Principal Investigator: John Grbic   Start date: 06/08/2008 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Surgery Division : Allen General Surgery GPS - **STUDY MANAGER** Prospective randomized trial comparing medical therapy to weight loss surgery in type 2 diabetics with BMI 30-35. Abbreviated Title: Diabetes Surgery Study   Principal Investigator: William B. Inabnet   Start date: 06/01/2008 End date: 05/31/2010 to request information from Principal Investigator.    Top of page Department : Surgery Division : Cardiothoracic Surgery **STUDY MANAGER** Evaluation of the VentrAssist Left Ventricular Assist Device as a Bridge to Cardiac Transplantation-Pivotal Trial   Principal Investigator: Yoshifumi Naka   Start date: 09/12/2007 End date: 03/31/2010 to request information from Principal Investigator.    Top of page **STUDY MANAGER** Prospective, multi-center, randomized clinical investigation of transmedics organ care system (OCS) for cardiac use   Principal Investigator: Yoshifumi Naka   Start date: 10/16/2008 End date: 04/30/2011 to request information from Principal Investigator.    Top of page **STUDY MANAGER** The Evaluation of the Safety and Effectiveness of the Duraheart Left Ventricular Assist System in Patients Awaiting Transplantation   Principal Investigator: Yoshifumi Naka   Start date: 10/13/2008 End date: 04/30/2011 to request information from Principal Investigator.    Top of page G050203 - **STUDY MANAGER** An Observational, Prospective Evaluation of the Trifecta Valve   Principal Investigator: Allan S. Stewart   Start date: 12/13/2007 End date: 06/30/2011 to request information from Principal Investigator.    Top of page MAGRIT - Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer   Principal Investigator: Joshua Sonett   Start date: 09/18/2007 End date: 03/31/2018 to request information from Principal Investigator.    Top of page Relay Trial - **STUDY MANAGER** A Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients with Thoracic Aortic Pathologies   Principal Investigator: Allan S. Stewart   Start date: 08/23/2007 End date: 06/30/2014 to request information from Principal Investigator.    Top of page Vaccine V710 - **STUDY MANAGER** A randomized, MC, 2-blind, Group sequential study to evaluate the efficacy, immunogenicity and safety of a single dose of Merck 0657nI Staphyloccoccus aureus Vaccine V710 in adult patients scheduled   Principal Investigator: Michael Argenziano   Start date: 09/30/2008 End date: 09/15/2011 to request information from Principal Investigator.    Top of page Ventrassist LVAD - **STUDY MANAGER** Evaluation of the VentrAssist Left Ventricular Assist Device for the Treatment of Advanced Heart Failure-Destination Therapy   Principal Investigator: Yoshifumi Naka   Start date: 01/31/2008 End date: 08/31/2010 to request information from Principal Investigator.    Top of page Department : Surgery Division : Center For Liver Disease & Transplantation **STUDY MANAGER** A Phase 2, Ramdomized, Open-Label study of the Safety, Antiviral Activity, Peginterferon Alfa 2B (Peg-intron) plus Ribavirn (Rebetol) versus peg-intron plus rebetol in subjects with hepatitits c virus Genotype 1 infection   Principal Investigator: Robert S. Brown   Start date: 03/29/2007 End date: 09/30/2009 to request information from Principal Investigator.    Top of page **STUDY MANAGER** A Phase 3 Study of 2 dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C.   Principal Investigator: Robert S. Brown   Start date: 05/27/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page **STUDY MANAGER** Comparison of Weight-based Dosed of Taribavirin with Peginterferon Alfa-2b Versus Ribavirin Combined with Peginterferon Alfa-2b in Therapy-naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection   Principal Investigator: Robert S. Brown   Start date: 06/29/2007 End date: 12/31/2009 to request information from Principal Investigator.    Top of page AI463-901 - **STUDY MANAGER** A Preliminary Assessment of Safety and Antiviral Activity of Open-Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic Hepatitis B who have Viremia on Monotherapy in other Entecavir Trials   Principal Investigator: Robert S. Brown   Start date: 04/17/2003 End date: 12/31/2009 to request information from Principal Investigator.    Top of page CTI - **STUDY MANAGER** Safety and Efficacy of the extracorporeal liver assist device (Elad) in patients with acute on chronic hepatitis (AOCH)   Principal Investigator: Robert S. Brown   Start date: 01/19/2009 End date: 07/19/2010 to request information from Principal Investigator.    Top of page GILEAD-0108 - **STUDY MANAGER** A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects   Principal Investigator: Robert S. Brown   Start date: 03/23/2006 End date: 09/30/2009 to request information from Principal Investigator.    Top of page GlobeImmune - **STUDY MANAGER** Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; and Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus   Principal Investigator: Robert S. Brown   Start date: 01/02/2008 End date: 07/31/2010 to request information from Principal Investigator.    Top of page MORE Registry - MORE Registry (Mycophenolic acid Observational Renal Transplant Program) A Phase IV, multi-center, prospective, observational study of the safety, effectiveness and tolerability of immunosuppressant regimens to treat renal transplant patie   Principal Investigator: Lloyd Ratner   Start date: 12/10/2007 End date: 06/30/2013 to request information from Principal Investigator.    Top of page Maribavir 1263-301 - **STUDY MANAGER** A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylatic use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegaloviurs Disease in Recipients of Orthotopic Liver Transplants   Principal Investigator: Robert S. Brown   Start date: 09/04/2007 End date: 01/30/2010 to request information from Principal Investigator.    Top of page NABI-4204 Follow-up - Clinical Trial to Collect Long Term Follow-up Data for Orthotopic Liver Transplantation Subjects Previously Enrolled in the Nabi-4204 Study.   Principal Investigator: Robert S. Brown   Start date: 01/18/2008 End date: 07/31/2010 to request information from Principal Investigator.    Top of page PATHWAY - Prospective, randomised, double-blind, placebo-controlled, parallel-group, international multicentre phase III trial of PI88-in the adjuvant treatment of post-resection hepatocullar carcinoma.   Principal Investigator: Jean Emond   Start date: 06/30/2008 End date: 11/30/2010 to request information from Principal Investigator.    Top of page RAD001 - **STUDY MANAGER** 24 Month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo   Principal Investigator: Robert S. Brown   Start date: 05/21/2008 End date: 01/04/2012 to request information from Principal Investigator.    Top of page RFHE3002 - **STUDY MANAGER** A Multicenter, Open-Label Trial to Evaluate ihe Long-Term Safety and Tolerabilty of Rifaximin 550 MG BID in Subjects with a History of Hepatic Encephalopathy   Principal Investigator: Robert S. Brown   Start date: 06/07/2007 End date: 12/31/2009 to request information from Principal Investigator.    Top of page SPRINT STUDY - Safety and Efficacy Study of SCH 503034 in Previouosly Untreated Subjects with Chronic Hepatitis C Infected With Genotype 1   Principal Investigator: Robert S. Brown   Start date: 03/31/2007 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Sprint Follow Up PO5063 - ** STUDY MANAGER** Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was administered for the Treatment of Chronic Hepatitis C   Principal Investigator: Robert S. Brown   Start date: 03/11/2008 End date: 09/30/2010 to request information from Principal Investigator.    Top of page VX08-950-111 - **STUDY MANAGER** A Randomized study of stopping treatment at 24 wks vs cont.treatment to 48 wks in treatment-naive subject with Genotype 1 Chronic hepatitis C who acieve and eRVR while rcv'ing Telaprevir, Pegasys and Copegus   Principal Investigator: Robert S. Brown   Start date: 11/06/2008 End date: 05/30/2011 to request information from Principal Investigator.    Top of page Vertex Rollover - ** STUDY MANAGER** A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys%AE) and Ribavirin (Copegus%AE) in Subjects Enrolled in   Principal Investigator: Robert S. Brown   Start date: 04/23/2008 End date: 10/31/2010 to request information from Principal Investigator.    Top of page Department : Surgery Division : Surgical Oncology ACOSOG - American College of Surgeon Oncology Group (ACOSOG) U10 CA76001   Principal Investigator: Bret Taback   Start date: 08/30/2006 End date: 08/29/2016 to request information from Principal Investigator.    Top of page Allovectin - Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7 compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma   Principal Investigator: Howard L. Kaufman   Start date: 08/30/2007 End date: 03/31/2014 to request information from Principal Investigator.    Top of page Bay 43-9006 - Phase 1 Open-Label, Dose-Finding Study of BAY 43-9006 (sorafenib) in high-risk hepatocellular cancer patients after liver transplantation.   Principal Investigator: Abby Siegel   Start date: 01/21/2009 End date: 07/31/2013 to request information from Principal Investigator.    Top of page COMPASSION USE STUDY: A Multicenter Treatment Protocol for compassionate Use of Ipilimumab monotherapy in subjects with resectable stage III or Stage IV melanoma.   Principal Investigator: Howard L. Kaufman   Start date: 06/06/2008 End date: 11/30/2010 to request information from Principal Investigator.    Top of page New Vaccine for Kidney Cancer   Principal Investigator: Howard L. Kaufman   Start date: 10/01/2007 End date: 09/30/2009 to request information from Principal Investigator.    Top of page Phase II Trial of sequntial high dose interleukin 3 followed by temozolomide and gm-csf in metastatic melanoma   Principal Investigator: Howard L. Kaufman   Start date: 10/03/2005 End date: 04/30/2011 to request information from Principal Investigator.    Top of page Preliminary Study of the Safety, Immunogenicity and Clinical Efficacy of Trovax Given in Conjunction with Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer Prelim Study of Trovax eith IL-2 for Stage IV Renal Cancer   Principal Investigator: Howard L. Kaufman   Start date: 08/26/2004 End date: 11/30/2009 to request information from Principal Investigator.    Top of page Randomized, DB, MC study comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Baccine, and Melanoma Vaccine, & Melanoma Vaccine Monotherapy in HLA-A*0201-Positive Pts w/ Previously treated unresectable stage III or IV Melanoma   Principal Investigator: Howard L. Kaufman   Start date: 07/12/2005 End date: 01/31/2011 to request information from Principal Investigator.    Top of page Department : Surgery Division : Surgical Specialties Study of the Perioperative use of Cetuximab in Colon Cancer Patients   Principal Investigator: Richard L. Whelan   Start date: 11/20/2007 End date: 05/31/2010 to request information from Principal Investigator.    Top of page ToGA - **STUDY MANAGER** TOGa™: A Randomized, Sham-Controlled Trial to Assess the Safety and Effectiveness of Transoral Gastroplasty in the Treatment of Morbid Obesity.   Principal Investigator: Marc Bessler   Start date: 05/23/2008 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Department : Surgery Division : Vascular Surgery **STUDY MANAGER** Evaluation of the Zilver PTX Vascular Stent in the Above-the-Knee Femoropoliteal Artery (Phase 2 Study)   Principal Investigator: Nicholas J. Morrissey   Start date: 08/09/2007 End date: 02/28/2013 to request information from Principal Investigator.    Top of page BENEFIT - **STUDY MGR** Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT   Principal Investigator: Mark A. Hardy   Start date: 10/16/2006 End date: 04/30/2010 to request information from Principal Investigator.    Top of page Benefit-EXT IM103-027 - Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immuno- suppression Trial - EXTended criteria donors (BENEFIT - EXT)   Principal Investigator: Mark A. Hardy   Start date: 11/03/2006 End date: 05/31/2010 to request information from Principal Investigator.    Top of page CHOICE-82910 - **STUDY MANAGER** CAROTID STENTING FOR HIGH SURGICAL RISK PATIENTS; EVALUATING OUTCOMES THROUGH THE COLLECTION OF CLINICAL EVIDENCE (“CHOICE”)   Principal Investigator: James F McKinsey   Start date: 06/26/2007 End date: 12/31/2012 to request information from Principal Investigator.    Top of page CREATE PAS - ** STUDY MANAGER** Carotid Revascularization with EV3 Arterial Technology Evolution Post Approval Study   Principal Investigator: John Karwowski   Start date: 07/18/2007 End date: 01/31/2013 to request information from Principal Investigator.    Top of page Dermal-LSR - Pivotal study to evaluate the efficacy and safety of Dermal - Living Skin Replacement (Dermal-LSR) in the treatment of chronic diabetic foot ulcers   Principal Investigator: Nicholas J. Morrissey   Start date: 03/09/2007 End date: 09/30/2011 to request information from Principal Investigator.    Top of page ENOVUS - Phase II evaluation of the safety and efficacy of the Trivascular ENOVUS Stent Graft System in the treatment of abdominal aortic aneurysms   Principal Investigator: James F McKinsey   Start date: 08/18/2005 End date: 02/28/2011 to request information from Principal Investigator.    Top of page Endovascular Exclusion of AAA in High Risk Patients with Large Aortic and Iliac Artery Anatomy   Principal Investigator: James F McKinsey   Start date: 02/27/2006 End date: 08/31/2011 to request information from Principal Investigator.    Top of page FUSION / ACCESS - Prospective Multicenter trial of the FUSION Vascular Access graft for patients who require early vascular access for hemodialysis   Principal Investigator: Nicholas J. Morrissey   Start date: 12/15/2005 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Fenestrated-AAA - **STUDY MANAGER** Study Assessing Safety and Effectiveness of Perivisceral Aortic Aneurysm Treatment With the Zenith Fenestrated AAA Endovascular Graft and the Effects on Organ and Extremity Perfusion.   Principal Investigator: James F McKinsey   Start date: 02/04/2008 End date: 08/31/2015 to request information from Principal Investigator.    Top of page LEAP - Two-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients   Principal Investigator: James F McKinsey   Start date: 10/12/2006 End date: 04/30/2012 to request information from Principal Investigator.    Top of page OASIS - Clinical Study of the Orbital Atherectomy System for the Treatment of Peripheral Vascular Stenosis   Principal Investigator: James F McKinsey   Start date: 03/27/2007 End date: 09/30/2011 to request information from Principal Investigator.    Top of page PROOF - Plaque Removal versus Open Bypass Surgery For Critical Limb   Principal Investigator: Nicholas J. Morrissey   Start date: 06/22/2007 End date: 12/31/2013 to request information from Principal Investigator.    Top of page PYTHAGORAS - **STUDY MANAGER** Prospective aneurYsm Trial: High AnGle AORfix™ bifurcAted Stent graft   Principal Investigator: James F McKinsey   Start date: 11/07/2006 End date: 05/31/2012 to request information from Principal Investigator.    Top of page Phase II/III, Randomized, Open-label, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofetil and Corticosteroids...de novo Renal Transplantation.   Principal Investigator: Mark A. Hardy   Start date: 09/01/2008 End date: 12/01/2010 to request information from Principal Investigator.    Top of page Randomized, Double-Blind, Placebo-Controlled, Dose response study of the safety and efficacy of Thymosin Beta 4 in the treatment of Patients with Pressure Ulcers   Principal Investigator: Mark A. Hardy   Start date: 03/09/2006 End date: 11/07/2009 to request information from Principal Investigator.    Top of page SONOMA - **STUDY MANAGER** A Carotid Stenting Surveillance Program   Principal Investigator: James F McKinsey   Start date: 09/04/2007 End date: 03/31/2013 to request information from Principal Investigator.    Top of page SWIFT - Femoropopliteal DiSease Treated With the SilverHawk Plaque Excision System: A Prospective Registry wIth Duplex Ultrasound Follow Up at Twelve months   Principal Investigator: James F McKinsey   Start date: 10/12/2006 End date: 04/30/2010 to request information from Principal Investigator.    Top of page VALOR - Evaluation of the Medtronic AVE Talent Thoracic Stent Graft System for Treatment of Thoracic Aortic Aneurysms   Principal Investigator: James F McKinsey   Start date: 03/31/2004 End date: 12/31/2010 to request information from Principal Investigator.    Top of page VIVA - **STUDY MANAGER** The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients with Rxtracranial Carotid Artery Stenosis using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System   Principal Investigator: James F McKinsey   Start date: 03/08/2006 End date: 09/30/2010 to request information from Principal Investigator.    Top of page Zenith - **STUDY MANAGER** Zenith TX2 THORACIC TAA Endovascular Graft Clinical Trial Protocol   Principal Investigator: James F McKinsey   Start date: 02/06/2004 End date: 12/31/2009 to request information from Principal Investigator.    Top of page Department : Urology Division : Oncology Combined Phase I & Phase II Trial of Intravesical Abraxane, a Biologically Interactive Albumin-Bound Paclitaxel, in the Treatment of Refractory Superficial Transitional Cell Bladder Cancer   Principal Investigator: James McKiernan   Start date: 01/09/2008 End date: 07/31/2011 to request information from Principal Investigator.    Top of page Comparative Study of PET/CT versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients with Renal Masses Using Iodine-124 labeled Chimeric G250   Principal Investigator: James McKiernan   Start date: 08/01/2008 End date: 06/30/2010 to request information from Principal Investigator.    Top of page Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate ADjuvant Hormonal Therapy (Eligard-leuprolide acetate) in Combination with Taxotere (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Th   Principal Investigator: Aaron Katz   Start date: 05/15/2006 End date: 11/30/2011 to request information from Principal Investigator.    Top of page Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder after Bacillus Calmette-Guerin Failure - Protocol #V-0046   Principal Investigator: James McKiernan   Start date: 08/10/2005 End date: 02/28/2021 to request information from Principal Investigator.    Top of page Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy   Principal Investigator: Mitchell C. Benson   Start date: 11/20/2007 End date: 05/31/2013 to request information from Principal Investigator.    Top of page SELECT - Selenium and Vitamin E Cancer Prevention Trial (SELECT)   Principal Investigator: Mitchell C. Benson   Start date: 06/01/2000 End date: 05/31/2013 to request information from Principal Investigator.    Top of page UCOP - Urological Cancer Outreach Program Purchase Service Agreement   Principal Investigator: Mitchell C. Benson   Start date: 04/22/1999 End date: 12/31/2009 to request information from Principal Investigator.    Top of page

Copyright © 1997-2009 Columbia University Medical Center